Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease
Phase 3
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 306
- Registration Number
- NCT00203138
A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT00203151
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
Phase 4
Terminated
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-10-18
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT00202995
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
Phase 2
Completed
- Conditions
- Relapse-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-01-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT00202982
- Locations
- 🇺🇸
The MS Center of Atlanta, Atlanta, Georgia, United States
🇺🇸Michigan Institute of Neurological Disorders, Farmington Hills, Michigan, United States
🇺🇸Center for Neurologic Study, La Jolla, California, United States
A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma
Completed
- Conditions
- Parkinson's DiseaseMalignant Melanoma
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-10-18
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 2106
- Registration Number
- NCT00203008
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
Phase 4
Terminated
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 414
- Registration Number
- NCT00203047
Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT00112411
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸North Carolina Clinical Research, Raleigh, North Carolina, United States
🇺🇸Allergy Associates Medical Group, Inc., San Diego, California, United States
Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-05-03
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 415
- Registration Number
- NCT00109668
- Locations
- 🇺🇸
Allergy Research Foundation, Los Angeles, California, United States
🇺🇸Asthma and Allergy Research Center, Sarasota, Florida, United States
🇺🇸Aero Allergy Research Labs of Savannah, Inc, Savannah, Georgia, United States
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
Phase 2
Completed
- Conditions
- DementiaAlzheimer's Disease
- First Posted Date
- 2005-02-25
- Last Posted Date
- 2009-07-15
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT00104273
- Locations
- 🇺🇸
Fort Wayne Neurological Center, Fort Wayne, Indiana, United States
🇺🇸Four Rivers Clinical Research, Paducah, Kentucky, United States
🇺🇸Northern Michigan Neurology, Traverse City, Michigan, United States
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Phase 2
Completed
- Conditions
- Glioblastoma Multiforme
- Interventions
- Drug: TP-38
- First Posted Date
- 2005-02-23
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00104091
© Copyright 2025. All Rights Reserved by MedPath